argenex SE (NASDAQ:ARGX) Receives Consensus Recommendation of “Moderate Buy” from Analysts

Posted by Stanley Muller on Aug 22nd, 2026

Shares of argenex SE (NASDAQ:ARGX – Get Free Report) have been assigned a consensus recommendation of “Moderate Buy” from the twenty-four analysts that are covering the stock, MarketBeat Ratings reports. Four analysts have rated the stock with a hold recommendation, eighteen have assigned a buy recommendation and two have given a strong buy recommendation to the company. The average 1-year price objective among brokers that have issued ratings on the stock in the last year is $1,118.2778.

Several analysts have commented on ARGX shares. Wall Street Zen lowered argenex from a “buy” rating to a “hold” rating in a report on Saturday, August 15th. Royal Bank Of Canada increased their target price on argenex from $1,025.00 to $1,100.00 and gave the company an “outperform” rating in a research report on Tuesday. Citigroup lifted their price target on shares of argenex from $1,152.00 to $1,182.00 and gave the company a “buy” rating in a research note on Tuesday, July 21st. Oppenheimer boosted their price target on shares of argenex from $1,014.00 to $1,037.00 and gave the stock an “outperform” rating in a report on Friday, July 24th. Finally, Weiss Ratings cut shares of argenex from a “hold (c+)” rating to a “hold (c)” rating in a research report on Thursday, July 23rd.

Check Out Our Latest Research Report on argenex

argenex News Summary

Here are the key news stories impacting argenex this week:

Positive Sentiment: Higher analyst price targets: Morgan Stanley raised its target to $1,230, HC Wainwright to $1,202, and Wedbush to $1,150. These revisions signal continued confidence in argenx’s commercial execution and pipeline potential. Morgan Stanley Raises argenex Price Target HC Wainwright Boosts argenex Price Target Wedbush Raises argenex Price Target
Positive Sentiment: Long-term earnings estimates increased: HC Wainwright lifted its FY2029 EPS forecast to $56.38 from $53.47 and its FY2030 forecast to $76.63 from $64.39. The firm maintained a Buy rating and a $1,202 target, supporting the view that earnings could accelerate substantially over the next several years. FY2027 Earnings Estimate for argenex Issued By HC Wainwright
Positive Sentiment: Positive VYVGART Hytrulo trial results: argenx discussed positive Phase 3 ALKIVIA results in autoimmune myositis. The update adds support for expanding VYVGART Hytrulo into another autoimmune indication, potentially increasing the drug’s long-term revenue opportunity. argenx Discusses Positive Phase 3 ALKIVIA Trial Results
Positive Sentiment: Additional bullish coverage: Citi assigned argenx a Buy rating, while Citizens JMP projected strong potential appreciation. The broader analyst support contributes to positive investor sentiment. argenx Receives a Buy from Citi Citizens JMP Forecasts Strong Price Appreciation
Neutral Sentiment: A comparison examining whether argenx’s global scale gives it an edge over Zai Lab is informative but does not represent a new company-specific operating announcement. argenx Global Scale Compared With Zai Lab

argenex Stock Performance

ARGX stock opened at $1,039.78 on Friday. argenex has a one year low of $658.60 and a one year high of $1,058.69. The firm has a market cap of $65.05 billion, a PE ratio of 39.93, a P/E/G ratio of 1.08 and a beta of 0.46. The firm’s fifty day moving average is $895.14 and its 200 day moving average is $827.21.

argenex (NASDAQ:ARGX – Get Free Report) last announced its quarterly earnings results on Tuesday, July 21st. The company reported $7.32 earnings per share for the quarter, beating the consensus estimate of $5.86 by $1.46. The firm had revenue of $1.54 billion during the quarter, compared to analyst estimates of $1.45 billion. argenex had a return on equity of 43.59% and a net margin of 32.19%. Research analysts predict that argenex will post 29.04 earnings per share for the current fiscal year.

Institutional Trading of argenex

A number of institutional investors and hedge funds have recently modified their holdings of ARGX. Syon Capital LLC lifted its stake in argenex by 4.2% in the 2nd quarter. Syon Capital LLC now owns 1,017 shares of the company’s stock valued at $944,000 after buying an additional 41 shares in the last quarter. denkapparat Operations GmbH boosted its holdings in argenex by 126.4% in the 2nd quarter. denkapparat Operations GmbH now owns 910 shares of the company’s stock worth $844,000 after buying an additional 508 shares during the last quarter. Concurrent Investment Advisors LLC increased its stake in argenex by 36.9% during the 2nd quarter. Concurrent Investment Advisors LLC now owns 375 shares of the company’s stock worth $347,000 after buying an additional 101 shares in the last quarter. Rehmann Capital Advisory Group acquired a new position in shares of argenex during the second quarter valued at approximately $206,000. Finally, Navellier & Associates Inc. raised its holdings in shares of argenex by 3.3% during the second quarter. Navellier & Associates Inc. now owns 7,257 shares of the company’s stock valued at $6,733,000 after acquiring an additional 234 shares during the last quarter. Hedge funds and other institutional investors own 60.32% of the company’s stock.

About argenex

(Get Free Report)

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.